Skip Navigation

About Neornat

Leadership

Nam Suk Woo

Nam Suk Woo

Founder / Chief Executive Officer
Chief Executive Officer & Chief Technology Officer

  • Professor, Department of Pathology, College of Medicine, The Catholic University of Korea (Current)
  • Director, Functional Transcr&#105ptome Research Institute, The Catholic University of Korea (Current)
  • B.S., M.S. and Ph.D. in Pharmacy, Sungkyunkwan University
  • Post-doctoral Fellow, Lab of Pathology, NCI, NIH, USA
  • Senior Scientist, Genome Institute of Singapore, Singapore
  • More than 254 SCI publications
  • 28 patent applications and registrations
  • Basic Medical Science Award, National Academy of Medicine of Korea (Pfizer Medical Research Award), 2014
  • Minister of Health and Welfare Award, 2015
  • Minister of Environment Award, 2013
  • Former reviewer, Ho-Am Prize in Medicine
  • Former reviewer for KOSDAQ technology-special listing in RNA therapeutics
Park Chang Won

Park Chang Won

Director, Head of Regulatory Science

  • Former Research Officer, Ministry of Food and Drug Safety
  • (General Toxicology, Neurotoxicology, Organ System Drugs, Anti-Infective and Anticancer Drugs, Review Coordination, Hazardous Substance Analysis, Cosmetics Research, Oncology Products, Pharmacology, Cardiovascular Imaging Devices, Medical Device Research)
  • Ph.D. in Pharmacy, Sungkyunkwan University
  • Prime Minister Commendation, Ministry of the Interior and Safety, 2009
  • Expert in non-clinical drug safety studies
  • Expert in safety and efficacy evaluation for pharmaceuticals and medical devices
Kim Sang Yean

Kim Sang Yean

Head of Non-Clinical Drug Development

  • Ph.D. in Tumor Biology, College of Medicine, The Catholic University of Korea
  • Major in RNA Cancer Biology
  • Major in Targeted RNA Therapy
  • 7 SCI papers including Oncogene, 3 patent applications
  • Expert in modified mouse lung cancer analysis
  • Lead for macrophage RNA immunotherapy development
  • Lead for siRNA mix therapeutics R&D
  • Lead for GLP toxicology and PK/PD evaluation.
Na Min Jeong

Na Min Jeong

Head of Efficacy and Lead Compound Development

  • Ph.D. in Tumor Biology, College of Medicine, The Catholic University of Korea
  • Major in DNA Repair & Cancer Biology
  • Major in RNA Variation & Cancer
  • 4 SCI papers including Experimental Molecular Medicine, 3 patent applications
  • Expert in real-time mouse liver cancer imaging analysis
  • Lead for targeted therapeutics against novel DNA repair enzymes
  • Lead for non-clinical efficacy evaluation
Yoon Jeong Hwan

Yoon Jeong Hwan

Head of Digestive Cancer RNA Therapeutics Development

  • Clinical Instructor, College of Medicine, The Catholic University of Korea (Current)
  • Ph.D. in Tumor Biology, College of Medicine, The Catholic University of Korea
  • Experience in early gastric cancer diagnosis development
  • 50 SCI papers including Cancer Communications, 13 patent applications
  • Expert in gastric cancer early diagnosis kits
  • Expert in targeted anticancer therapeutics for gastric tumorigenesis
  • Lead investigator for efficacy, lead compound development and validation in gastric cancer therapeutics